Loading...
Market
What will be the resolution of Vertex Pharmaceuticals' lawsuit against HHS regarding Casgevy fertility support program by end of 2024?
2
Resolution / Starting Odds
Vertex allowed to pay for fertility treatment • 25%
Vertex not allowed to pay for fertility treatment • 25%
Settlement with conditions • 25%
Case unresolved • 25%
Court rulings and official announcements from Vertex Pharmaceuticals or the U.S. Department of Health and Human Services
Story
Vertex Pharmaceuticals Sues US Government Over Casgevy CRISPR Treatment Fertility Support Program
Jul 15, 2024, 06:15 PM
Vertex Pharmaceuticals has filed a lawsuit against the U.S. Department of Health and Human Services (HHS), seeking a court declaration that a fertility support program for patients prescribed its gene editing therapy, Casgevy, does not violate federal anti-kickback laws. The CRISPR treatment, which is used to treat sickle cell disease and beta thalassemia, carries a high risk of infertility. Vertex argues that the federal rule blocking access to fertility preservation services for these patients is problematic and seeks permission to pay for fertility treatment for individuals undergoing the Casgevy therapy.
View original story
Similar markets
Vertex wins • 25%
US government wins • 25%
Settlement reached • 25%
Case dismissed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
Indifferent • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Announce internal policy changes • 25%
Face additional lawsuits • 25%
No significant actions taken • 25%
Announce new partnerships or acquisitions • 25%
Settlement reached • 25%
FTC wins the case • 25%
PBMs win the case • 25%
Case is ongoing • 25%
Verdict upheld • 25%
Verdict overturned • 25%
Settlement reached • 25%
Other • 25%
Favorable ruling for Cassava Sciences • 25%
Unfavorable ruling for Cassava Sciences • 25%
Settlement • 25%
Case dismissed • 25%
Cassava Sciences wins the lawsuits • 25%
Cassava Sciences settles the lawsuits • 25%
Cassava Sciences loses the lawsuits • 25%
Lawsuits are dismissed • 25%